Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care : published form 20-F for the fiscal year 2019

share with twitter share with LinkedIn share with facebook
02/21/2020 | 09:02am EDT

Press Release

Fresenius Medical Care, the world's largest provider of dialysis products and services, has filed the annual report 2019 on form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at the company's website in the 'Investors ' section as well as at the SEC's website (www.sec.gov).

A hard copy of Fresenius Medical Care's annual report on form 20-F including the complete audited financial statements may be obtained from the company free of charge upon request to the company's Investor Relations department by email at ir(at)fmc-ag.com.

The company also published a Facts & Figures 2019 website at factsandfigures.fmc-ag.com to provide an overview of the key financial figures for the fiscal year 2019. In addition, the new Corporate Magazine, Company Profile as well as a Five-Year-Summary are available for download.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,994 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 345,096 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

Disclaimers
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Disclaimer

FMC - Fresenius Medical Care AG & Co. KGaA published this content on 21 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 February 2020 13:01:05 UTC


share with twitter share with LinkedIn share with facebook
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
10:45aFRESENIUS MEDICAL CARE : continues solid revenue and strong earnings growth in t..
AQ
10:19aFMC FRESENIUS MEDICAL CARE AG & CO K : Kepler Cheuvreux keeps its Buy rating
MD
08:56aFMC FRESENIUS MEDICAL CARE AG & CO K : Buy rating from Independant Research
MD
03:57aFMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan remains its Buy rating
MD
10/29FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 50 of the Wp..
EQ
10/29FRESENIUS SE : Berenberg maintains a Buy rating
MD
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Berenberg reiterates its Buy rating
MD
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from UBS
MD
10/29FMC FRESENIUS MEDICAL CARE AG & CO K : Warburg Research sticks Neutral
MD
10/29FRESENIUS SE : Warburg Research remains its Buy rating
MD
More news
Financials (USD)
Sales 2020 21 200 M - -
Net income 2020 1 543 M - -
Net Debt 2020 13 866 M - -
P/E ratio 2020 14,8x
Yield 2020 1,74%
Capitalization 22 634 M 22 604 M -
EV / Sales 2020 1,72x
EV / Sales 2021 1,59x
Nbr of Employees 124 736
Free-Float 65,1%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 96,13 $
Last Close Price 77,29 $
Spread / Highest target 48,5%
Spread / Average Target 24,4%
Spread / Lowest Target -17,7%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors